• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AABB Revises TRALI Mitigation Requirements

October 11, 2013

The AABB’s Blood Bank/Transfusion Service Standards Program Unit has revised requirements regarding the mitigation of transfusion-related acute lung injury (TRALI). The updated requirements address an exemption previously specified in the 29th edition of Standards for Blood Banks and Transfusion Services. They will continue to require that “plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.” Initial requirements specified acceptable donors for “high plasma volume components,” and exempted apheresis platelets collected in platelet additive solution (PAS) from these standards. This exemption sparked concern, however, due to the residual plasma volume remaining in platelets collected in PAS still possibly causing TRALI. Consequently, platelets are no longer included in this standard.

 

Reference

1.   AABB Weekly Report. AABB Revises and Clarifies TRALI Risk Reduction Requirements. Sept 27, 2013. Accessed online: http://www.aabb.org/resources/publications/weeklyreport/Pages/default.aspx

Filed Under

  • Blood Donation
  • News
  • Quality Control and Regulatory

Recommended

  • Gunshot Wounds Cause Significant Mortality, Blood Utilization, and Health Care Costs in the U.S.

  • Prophylactic Platelet Transfusions are Not Superior to Supportive Care for Dengue Patients with Thrombocytopenia

  • Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley